ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Short Interest Update

Posted by Stacy Sanders on Jan 30th, 2025

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Get Free Report) was the target of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 5,200 shares, a growth of 136.4% from the December 31st total of 2,200 shares. Based on an average daily volume of 10,900 shares, the short-interest ratio is currently 0.5 days.

ProShares Ultra Nasdaq Biotechnology Stock Performance

Shares of BIB traded up $1.19 during mid-day trading on Thursday, reaching $56.01. The stock had a trading volume of 6,411 shares, compared to its average volume of 8,543. The business has a fifty day moving average of $54.20 and a 200 day moving average of $60.49. ProShares Ultra Nasdaq Biotechnology has a 12 month low of $47.19 and a 12 month high of $69.56.

ProShares Ultra Nasdaq Biotechnology Increases Dividend

The company also recently declared a dividend, which was paid on Tuesday, December 31st. Investors of record on Monday, December 23rd were issued a $0.3964 dividend. This is a positive change from ProShares Ultra Nasdaq Biotechnology’s previous dividend of $0.15. The ex-dividend date of this dividend was Monday, December 23rd.

Institutional Inflows and Outflows

An institutional investor recently raised its position in ProShares Ultra Nasdaq Biotechnology stock. Jane Street Group LLC increased its stake in shares of ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Free Report) by 8.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,803 shares of the exchange traded fund’s stock after acquiring an additional 374 shares during the period. Jane Street Group LLC owned about 0.35% of ProShares Ultra Nasdaq Biotechnology worth $306,000 as of its most recent filing with the Securities & Exchange Commission.

ProShares Ultra Nasdaq Biotechnology Company Profile

(Get Free Report)

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.